310 related articles for article (PubMed ID: 30845975)
21. Simulating and predicting cellular and in vivo responses of colon cancer to combined treatment with chemotherapy and IAP antagonist Birinapant/TL32711.
Crawford N; Salvucci M; Hellwig CT; Lincoln FA; Mooney RE; O'Connor CL; Prehn JH; Longley DB; Rehm M
Cell Death Differ; 2018 Nov; 25(11):1952-1966. PubMed ID: 29500433
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of birinapant in combination with carboplatin in targeting platinum‑resistant epithelial ovarian cancers.
Singh T; Neal A; Dibernardo G; Raheseparian N; Moatamed NA; Memarzadeh S
Int J Oncol; 2022 Mar; 60(3):. PubMed ID: 35191515
[TBL] [Abstract][Full Text] [Related]
23. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma.
Zheng Z; Fan S; Zheng J; Huang W; Gasparetto C; Chao NJ; Hu J; Kang Y
J Hematol Oncol; 2018 Feb; 11(1):29. PubMed ID: 29482577
[TBL] [Abstract][Full Text] [Related]
25. Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies.
Condon SM; Mitsuuchi Y; Deng Y; LaPorte MG; Rippin SR; Haimowitz T; Alexander MD; Kumar PT; Hendi MS; Lee YH; Benetatos CA; Yu G; Kapoor GS; Neiman E; Seipel ME; Burns JM; Graham MA; McKinlay MA; Li X; Wang J; Shi Y; Feltham R; Bettjeman B; Cumming MH; Vince JE; Khan N; Silke J; Day CL; Chunduru SK
J Med Chem; 2014 May; 57(9):3666-77. PubMed ID: 24684347
[TBL] [Abstract][Full Text] [Related]
26. Combinatorial Treatment of Birinapant and Zosuquidar Enhances Effective Control of HBV Replication In Vivo.
Morrish E; Mackiewicz L; Silke N; Pellegrini M; Silke J; Brumatti G; Ebert G
Viruses; 2020 Aug; 12(8):. PubMed ID: 32824616
[TBL] [Abstract][Full Text] [Related]
27. Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer.
Noonan AM; Bunch KP; Chen JQ; Herrmann MA; Lee JM; Kohn EC; O'Sullivan CC; Jordan E; Houston N; Takebe N; Kinders RJ; Cao L; Peer CJ; Figg WD; Annunziata CM
Cancer; 2016 Feb; 122(4):588-597. PubMed ID: 26566079
[TBL] [Abstract][Full Text] [Related]
28. Targeting triple-negative breast cancers with the Smac-mimetic birinapant.
Lalaoui N; Merino D; Giner G; Vaillant F; Chau D; Liu L; Kratina T; Pal B; Whittle JR; Etemadi N; Berthelet J; Gräsel J; Hall C; Ritchie ME; Ernst M; Smyth GK; Vaux DL; Visvader JE; Lindeman GJ; Silke J
Cell Death Differ; 2020 Oct; 27(10):2768-2780. PubMed ID: 32341449
[TBL] [Abstract][Full Text] [Related]
29. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.
Malek E; Driscoll JJ
Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530
[TBL] [Abstract][Full Text] [Related]
30. β-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma.
Savvidou I; Khong T; Cuddihy A; McLean C; Horrigan S; Spencer A
Mol Cancer Ther; 2017 Sep; 16(9):1765-1778. PubMed ID: 28500235
[TBL] [Abstract][Full Text] [Related]
31. DANFIN functions as an inhibitor of transcription factor NF-κB and potentiates the antitumor effect of bortezomib in multiple myeloma.
Uematsu A; Kido K; Manabe E; Takeda H; Takahashi H; Hayashi M; Imai Y; Sawasaki T
Biochem Biophys Res Commun; 2018 Jan; 495(3):2289-2295. PubMed ID: 29284118
[TBL] [Abstract][Full Text] [Related]
32. Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant.
Richmond J; Robbins A; Evans K; Beck D; Kurmasheva RT; Billups CA; Carol H; Heatley S; Sutton R; Marshall GM; White D; Pimanda J; Houghton PJ; Smith MA; Lock RB
Cancer Res; 2016 Aug; 76(15):4579-91. PubMed ID: 27302164
[TBL] [Abstract][Full Text] [Related]
33. Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma.
Xie Y; Liu J; Jiang H; Wang J; Li X; Wang J; Zhu S; Guo J; Li T; Zhong Y; Zhang Q; Liu Z
Oncogene; 2020 Jan; 39(4):922-934. PubMed ID: 31576013
[TBL] [Abstract][Full Text] [Related]
34. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
[TBL] [Abstract][Full Text] [Related]
35. Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway-Dependent Apoptosis.
Xie X; Lee J; Liu H; Pearson T; Lu AY; Tripathy D; Devi GR; Bartholomeusz C; Ueno NT
Mol Cancer Ther; 2021 Feb; 20(2):296-306. PubMed ID: 33323457
[TBL] [Abstract][Full Text] [Related]
36. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma.
Berenson JR; Ma HM; Vescio R
Semin Oncol; 2001 Dec; 28(6):626-33. PubMed ID: 11740821
[TBL] [Abstract][Full Text] [Related]
37. A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo.
Watanabe M; Dewan MZ; Okamura T; Sasaki M; Itoh K; Higashihara M; Mizoguchi H; Honda M; Sata T; Watanabe T; Yamamoto N; Umezawa K; Horie R
Int J Cancer; 2005 Mar; 114(1):32-8. PubMed ID: 15523684
[TBL] [Abstract][Full Text] [Related]
38. Homoharringtonine enhances bortezomib antimyeloma activity in myeloma cells adhesion to bone marrow stromal cells and in SCID mouse xenografts.
Chen P; Yuan Q; Yang H; Wen X; You P; Hou D; Xie J; Cheng Y; Huang H
Leuk Res; 2017 Jun; 57():119-126. PubMed ID: 28463768
[TBL] [Abstract][Full Text] [Related]
39. Blocking of Transient Receptor Potential Vanilloid 1 (TRPV1) promotes terminal mitophagy in multiple myeloma, disturbing calcium homeostasis and targeting ubiquitin pathway and bortezomib-induced unfolded protein response.
Beider K; Rosenberg E; Dimenshtein-Voevoda V; Sirovsky Y; Vladimirsky J; Magen H; Ostrovsky O; Shimoni A; Bromberg Z; Weiss L; Peled A; Nagler A
J Hematol Oncol; 2020 Nov; 13(1):158. PubMed ID: 33239060
[TBL] [Abstract][Full Text] [Related]
40. Effects of Birinapant on Proliferation and Invasion of MGC-803 Gastric Cancer Cells and Mechanism Underlying These Effects.
Zhu DL; Shuai LY
Bull Exp Biol Med; 2021 May; 171(1):56-61. PubMed ID: 34050412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
